ORPHA:231111
Drug-induced lupus erythematosus
Also known as: DILE
Publications
2,153
Trials
0
Interventional, condition-specific
Researchers
972
Distinct authors in sample
Gene link
—
Readiness
3/6
Stages with a signal
Clinical definition (Orphanet)
A rare, systemic disease with skin involvement characterized by the onset of lupus erythematosus-like signs and symptoms resulting from continuous drug intake (>1 month), which resolve when treatment is discontinued, in persons with no history of autoimmune disease. Manifestations are variable and may be systemic (e.g. arthralgia, myalgia, fever, fatigue, serositis, pleuritis, pericarditis), subacute cutaneous (incl. photosensitive, non-scarring, annular, polycyclic or papulosquamous lesions, malar erythema, vasculitis, bullous lesions, erythema multiforme-like changes), and/or chronic cutaneous (typically discoid lesions in sun-exposed areas). Procainamide and hydralazine are the drugs most frequently implicated.
How rare: How common this is has not been clearly measured.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0016474
- UMLS:C0263591
- NCIT:C114354
Additional Mondo synonyms (3)
drug induced lupus · drug induced lupus erythematosus · drug-induced lupus
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
3/6 stages with a signal
No specific-condition interventional trial, but broader-category trials exist — discuss eligibility with a clinician.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
2,153 matched papers (1,018 in last 10 years) Source
- Phenotype characterisedPresent
23 HPO annotations (e.g. Petechiae; Pericardial effusion; Myalgia) Source
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPartial
None under the specific name; 932 for broader category lupus erythematosus
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
23
Associated phenotypes · MONDO:0016474
- Petechiae
- Pericardial effusion
- Myalgia
- Elevated erythrocyte sedimentation rate
- Prolonged QTc interval
Showing 5 of 23 — open Monarch for the full list.
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
2,153
2,153 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
2,153 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
1,018 in the last 10 years · low confidence
Phrase hits: 2,153 · MeSH hits: 0
Who's working on it?
972
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Lee AYS4 papers · 2026
Institute of Clinical Pathology and Medical Research/Westmead Hospital.
Papers in Europe PMC - 02Bains K3 papers · 2026
Department of Internal Medicine, Banner University Medical Center, Tucson, AZ, USA.
Papers in Europe PMC - 03Barbaud A3 papers · 2022
Faculté de Médecine Sorbonne Université, AP-HP, Service de Dermatologie et Allergologie, Hôpital Tenon, Paris, France.
Papers in Europe PMC - 04Chasset F3 papers · 2022
Faculté de Médecine Sorbonne Université, AP-HP, Service de Dermatologie et Allergologie, Hôpital Tenon, Paris, France.
Papers in Europe PMC - 05Liu J3 papers · 2025
Department of Gastroenterology, Nanjing Drum Tower Hospital, Clinical College of Nanjing Medical University, Nanjing, China.
Papers in Europe PMC - 06Manzo C3 papers · 2021
Gerontorheumatologic Outpatient Service, Mariano Lauro Hospital, Naples 80063, Italy.
Papers in Europe PMC - 07Minchenberg SB3 papers · 2026
Division of Gastroenterology & Hepatology, Beth Israel Deaconess Medical Center, Boston, MA, 02115, USA.
Papers in Europe PMC - 08Prabakaran S3 papers · 2026
NonExomics, Inc.,, 2 Simon Willard Road, Acton, MA, 01720, USA. sudhakaran.prabakaran@nonexomics.com.
Papers in Europe PMC - 09Sudhakaran SC3 papers · 2026
Acton-Boxborough Regional High School, Acton, MA, 01720, USA.
Papers in Europe PMC - 10Wayland MT3 papers · 2026
Department of Zoology, University of Cambridge, Downing Street, Cambridge, CB2 3EJ, UK.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present). 932 trials are registered for lupus erythematosus, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 11 September 2026 · last trial check 11 September 2026
No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.
low confidence · 38.6th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
932 interventional trials matched lupus erythematosus, the broader category — listed below. Those studies are not counted in the condition-specific total.
Broader category: lupus erythematosus
932
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT07332481·RECRUITING·A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease
Conditions: Systemic Lupus Erythematosus (SLE) · Cutaneous Lupus Erythematosus (CLE)·Matched via name phrase
- NCT07778446·NOT YET RECRUITING·A Study to Test CRT-402 in Refractory Autoimmune Disease
Conditions: Autoimmune Diseases · Systemic Lupus Erythematosus · Systemic Scleroderma · Myositis·Matched via name phrase
- NCT07212322·NOT YET RECRUITING·A Study of CD19 UCAR-T Cells in Subjects With Autoimmune Diseases
Conditions: Systemic Lupus Erythematosus · Idiopahic Inflammatory Myopathies · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis · Sjögren's Syndrome·Matched via name phrase
- NCT06356740·NOT YET RECRUITING·Efficacy and Tolerance of Abacavir/Lamivudine Treatment in Patients With Systemic Lupus Erythematosus
Conditions: Systemic Lupus Erythematosus·Matched via name phrase
- NCT07749430·NOT YET RECRUITING·A Clinical Study of ACG102 Injection in Patients With Refractory Active Systemic Lupus Erythematosus
Conditions: Refractory Active Systemic Lupus Erythematosus·Matched via name phrase
- NCT06822881·RECRUITING·CT1190B in the Treatment of Patients With Moderate to Severe Refractory Systemic Lupus Erythematosus (SLE) or Refractory/Progressive Systemic Sclerosis (SSc)
Conditions: Systemic Lupus Erythematosus (SLE) · Systemic Sclerosis (SSc)·Matched via name phrase
- NCT07315087·RECRUITING·CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases
Conditions: SLE - Systemic Lupus Erythematosus · SSc-Systemic Sclerosis · IIM- Idiopathic Inflammatory Myopathies · ANCA Associated Vasculitis (AAV)·Matched via name phrase
- NCT05097365·ENROLLING BY INVITATION·Methyl-donor Nutrient Supplementation and Methylation Profile in Lupus Patients With Obesity
Conditions: Overweight and Obesity · Lupus Erythematosus·Matched via name phrase
- NCT06400537·RECRUITING·Clinical Study of A-319 in the Treatment of Active/Refractory Systemic Lupus Erythematosus
Conditions: Systemic Lupus Erythematosus·Matched via name phrase
- NCT07364396·NOT YET RECRUITING·Efficacy and Safety of CRC01 in Participants With Severe, Refractory Systemic Lupus Erythematosus
Conditions: Lupus Nephritis · Lupus Nephritis (LN) · SLE · SLE (Systemic Lupus)·Matched via name phrase
- NCT07555626·NOT YET RECRUITING·Mediterranean Diet and Gut Microbiota in Children With Systemic Lupus Erythematosus
Conditions: Systemic Lupus Erythematosus (SLE)·Matched via name phrase
- NCT06794008·RECRUITING·BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases
Conditions: Systemic Lupus Erythematosus · Inflammatory Myopathy · Systemic Sclerosis (SSc) · ANCA-associated Vasculitis·Matched via name phrase
- NCT07219563·RECRUITING·Alnuctamab for Refractory SLE (LATTE Study)
Conditions: Systemic Lupus Erythematosus·Matched via name phrase
- NCT06032923·RECRUITING·Double-blind Placebo Controlled Study to Evaluate the Effect of NAD+ Boosting With Nicotinamide Riboside on Immunometabolism and Immunity in Systemic Lupus Erythematosus
Conditions: Systemic Lupus Erythematosus (Sle)·Matched via name phrase
- NCT07174843·RECRUITING·An Exploratory Study of CD19/CD22/BCMA CAR-T Cells (BZE2204) in Subjects With Relapsed or Refractory Autoimmune Diseases
Conditions: Idiopathic Inflammatory Myopathies(IIM) · Immune Thrombocytopenia(ITP) · Systemic Lupus Erythematosus(SLE)·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 32 · after dedupe 32 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 32 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (32)
- isrctn·ISRCTN22102770·Recruiting·A study to test the safety and effects of a New Drug (LAE103) in healthy people who are overweight or obese, and in healthy postmenopausal women. The study also looks at how LAE103 works when taken alone or together with another drug (LAE102).
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN84894190·No longer recruiting·Immune imbalance in pediatric persistent immune thrombocytopenia
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN49040930·No longer recruiting·A long-term study to assess the safety and efficacy of a gel treatment in subjects with Acne Vulgaris
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN83474167·No longer recruiting·Phase II open-label trial of atezolizumab in patients with urinary tract squamous cell carcinoma
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN22771691·No longer recruiting·A study to investigate if atezolizumab can reduce the size of urothelial cancer before surgery and to determine how the drug works
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN11595117·No longer recruiting·A study evaluating single-agent inavolisib and inavolisib plus atezolizumab in PIK3CA-mutated cancers
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN17038127·No longer recruiting·A study investigating if a new medication, bintrafusp alfa, can reduce the size of urothelial carcinoma, a type of bladder cancer, before surgery to remove the bladder
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN11965217·No longer recruiting·A trial to assess whether the addition of atezolizumab to current standard treatment for patients with relapsed or refractory Diffuse Large B-Cell Lymphoma, who are not able to have high dose therapy, improves survival outcomes
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN61697120·No longer recruiting·GuARD - GR1014 cutaneous gel Against Radiation Dermatitis
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN13629437·No longer recruiting·Plasma exchange therapy with the crossflow membrane filtration method for post-COVID-19 conditions
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN53212600·Stopped·Trial to investigate if the addition of two novel immunotherapy agents in combination with a chemotherapy agent can reduce the size of the cancer and how long they can delay the growth of the cancer in patients with metastatic pancreatic cancer.
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN12427150·No longer recruiting·A study to see whether adalimumab or secukinumab is better for treating children and young people with juvenile idiopathic arthritis (JIA) associated uveitis or chronic anterior uveitis
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN16338908·No longer recruiting·Patients with congenital antithrombin deficiency undergoing a pharmacokinetic assessment, surgery or giving birth are treated with Atenativ, an antithrombin concentrate
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN13649456·No longer recruiting·A study of three malaria vaccines to prevent the transmission of malaria in adults in Mali: TBVax2
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN12669009·No longer recruiting·Clinical trial of whether AZD5069 combined with immunotherapy (durvalumab) is effective for patients with advanced primary liver cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN15354495·No longer recruiting·Randomised trial optimising COVID-19 vaccination in patients with chronic health conditions and a poor response to standard vaccination
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN13007439·No longer recruiting·Treatment of iron deficiency anaemia in pregnancy study
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN53348826·No longer recruiting·Renal Adjuvant Multiple Arm Randomised Trial (RAMPART)
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN64574169·No longer recruiting·Exploring the role of thrombophilias in women with recurrent pregnancy loss and its treatment
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN41478539·No longer recruiting·Comparing alternative regimens for escalating treatment of intermediate and high-risk oropharyngeal cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN79284836·Stopped·Prospective multi-centre observational pilot study to investigate the safety and efficacy of the Venous Window Needle GuideTM (VWNG) (SAVE-2 study)
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN68772788·No longer recruiting·Study to compare the treatment effects of Ginkgo biloba extract EGb 761® and Pentoxifylline in patients who suffer from tinnitus for more than three months and from psychological and social problems caused by the tinnitus
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN19073445·No longer recruiting·Atorvastatin and endothelial function in systemic lupus erythematosus (SLE) patients
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN28462186·No longer recruiting·A phase 2 pilot study of the safety, pharmacokinetics, and pharmacodynamics of ARC1779 injection in patients with von Willebrand factor-related platelet function disorders
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN05212803·No longer recruiting·Efficacy and tolerability of 5-Loxin®, a novel standardised Boswellia serrata extract in the treatment of Osteoarthritis of knee: a randomised, double blind placebo controlled clinical trial
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Drug-induced lupus erythematosus — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Drug-induced lupus erythematosus" OR "drug induced lupus" OR "drug induced lupus erythematosus" OR "drug-induced lupus"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Drug-induced lupus erythematosus" OR "drug induced lupus" OR "drug induced lupus erythematosus" OR "drug-induced lupus"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"lupus erythematosus"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Synonyms dropped by stoplist: DILE
Confidence reasoning
- Preferred label is multi-word and distinctive
- 1 synonym(s) dropped by stoplist (may under-count)
- No label/synonym collisions with other diseases in this corpus
- Publication count (2153) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity
Ingested 2026-07-27T10:13:11.427Z
